Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk
- PMID: 22005924
- PMCID: PMC3393766
- DOI: 10.1183/09031936.00145411
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk
Abstract
Resistance to anti-tuberculosis (TB) medicines is a major public health threat in most countries of the former Soviet Union. As no representative and quality-assured information on the magnitude of this problem existed in Belarus, a survey was conducted in the capital city of Minsk. Between November 2009 and December 2010, 156 consecutively diagnosed new and 68 previously treated culture-positive TB patients residing in Minsk were enrolled in the survey. Mycobacterium tuberculosis isolates were obtained from each patient and tested for susceptibility to first- and second-line anti-TB drugs. Multidrug-resistant (MDR)-TB was found in 35.3% (95% CI 27.7-42.8) of new patients and 76.5% (95% CI 66.1-86.8) of those previously treated. Overall, nearly one in two patients enrolled had MDR-TB. Extensively drug-resistant TB was reported in 15 of the 107 MDR-TB patients (14.0%, 95% CI 7.3-20.7). Patients <35 yrs of age have shown a two times higher odds ratio of multidrug-resistant TB than those aged >35 yrs. The findings of this survey in Minsk city are alarming and represent the highest proportions of MDR-TB ever recorded in the world. This study greatly contributes to the understanding of the burden of drug-resistant TB in urban areas of Belarus.
Conflict of interest statement
None declared.
Figures
Comment in
-
Re-think first-line tuberculosis treatment.Eur Respir J. 2013 Feb;41(2):488-9. doi: 10.1183/09031936.00112612. Eur Respir J. 2013. PMID: 23370809 No abstract available.
Similar articles
-
Whole-Genome Sequencing of Mycobacterium tuberculosis Provides Insight into the Evolution and Genetic Composition of Drug-Resistant Tuberculosis in Belarus.J Clin Microbiol. 2017 Feb;55(2):457-469. doi: 10.1128/JCM.02116-16. Epub 2016 Nov 30. J Clin Microbiol. 2017. PMID: 27903602 Free PMC article.
-
A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.BMC Infect Dis. 2018 Apr 2;18(1):149. doi: 10.1186/s12879-018-3053-5. BMC Infect Dis. 2018. PMID: 29606091 Free PMC article.
-
Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011.Euro Surveill. 2013 Oct 17;18(42):20609. doi: 10.2807/1560-7917.es2013.18.42.20609. Euro Surveill. 2013. PMID: 24176581
-
[Management of multidrug-resistant tuberculosis].Rev Pneumol Clin. 2015 Apr-Jun;71(2-3):130-9. doi: 10.1016/j.pneumo.2014.05.001. Epub 2014 Aug 19. Rev Pneumol Clin. 2015. PMID: 25153927 Review. French.
-
Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).Tuberculosis (Edinb). 2018 Jul;111:20-30. doi: 10.1016/j.tube.2018.04.008. Epub 2018 May 3. Tuberculosis (Edinb). 2018. PMID: 30029909 Review.
Cited by
-
Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28507117 Free PMC article.
-
One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America.AIDS. 2017 Jan 28;31(3):375-384. doi: 10.1097/QAD.0000000000001333. AIDS. 2017. PMID: 28081036 Free PMC article.
-
Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance.Nat Commun. 2018 Oct 17;9(1):4306. doi: 10.1038/s41467-018-06634-y. Nat Commun. 2018. PMID: 30333483 Free PMC article.
-
Modular programming for tuberculosis control, the "AuTuMN" platform.BMC Infect Dis. 2017 Aug 7;17(1):546. doi: 10.1186/s12879-017-2648-6. BMC Infect Dis. 2017. PMID: 28784094 Free PMC article.
-
Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country.Eur Respir J. 2013 Nov;42(5):1291-301. doi: 10.1183/09031936.00111812. Epub 2012 Oct 25. Eur Respir J. 2013. PMID: 23100496 Free PMC article.
References
-
- Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33: 1085–1094 - PubMed
-
- Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J 2010; 36: 584–593 - PubMed
-
- Migliori GB, Sotgiu G, Lange C, et al. Extensively drug-resistant tuberculosis: back to the future. Eur Respir J 2010; 36: 475–477 - PubMed
-
- Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623–626 - PubMed
-
- Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871–881 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials